Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11743754 | 0.79 | EDNRA (0.58) | ALDH1A1MAPTHPGDEDNRAKDM4E | |
| SCHEMBL5279040 | 0.78 | EDNRA (0.62) | ALDH1A1MAPTHPGDEDNRAKDM4E | |
| SCHEMBL4988618 | 0.78 | POLB (0.38) | ALDH1A1HPGDKDM4EL3MBTL1CYP1B1 | |
| SCHEMBL4994482 | 0.74 | MCL1 (0.42) | ALDH1A1HPGDKDM4EL3MBTL1GPR35 | |
| SCHEMBL4985293 | 0.73 | ALDH1A1 (0.42) | ALDH1A1MAPTHPGDKDM4EHSD17B10 | |
| SCHEMBL6828445 | 0.69 | CA12 (0.46) | ALDH1A1HPGDL3MBTL1CYP1A2CA9 | |
| SCHEMBL4982792 | 0.69 | SIRT2 (0.47) | ALDH1A1HPGDKDM4EL3MBTL1MAOA | |
| SCHEMBL4992715 | 0.68 | ALDH1A1 (0.39) | ALDH1A1MAPTHPGDKDM4EHSD17B10 | |
| SCHEMBL4989165 | 0.68 | MCL1 (0.39) | ALDH1A1MAPTHPGDKDM4EHSD17B10 | |
| SCHEMBL31347959 | 0.67 | EDNRA (0.41) | MAPTEDNRAKDM4EHSD17B10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-7045514-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-7026314-B2 | Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist | ASTRAZENECA AB (SE) | 2006-04-11 | — | — | US | disclosed |
| US-20060019947-A1 | Therapeutic chromone compounds | CHAPDELAINE MARC | 2006-01-26 | — | — | US | disclosed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| US-20050096312-A1 | Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders | ASTRAZENECA AB (SE) | 2005-05-05 | — | — | US | disclosed |
| US-20050085457-A1 | Therapeutic quinolone compounds with 5-ht-antagonistic properties | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | PIERSON EDWARD (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | disclosed |
| EP-1353914-A2 | THERAPEUTIC CHROMONE COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353913-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003037871-A1 | THERAPEUTIC QUINOLONE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037872-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | ALDH1A1 592/4885MAPT 698/4885HPGD 658/4885 |
| US-20060178372-A1 | Therapeutic quinoline compounds | HTR1B, HTR3B, HTR1A | ALDH1A1 922/4885MAPT 628/4885HPGD 1249/4885 |
| US-20050085457-A1 | Therapeutic quinolone compounds with 5-ht-antagonistic properties | HTR1B, HTR1A, HTR1D | ALDH1A1 2147/4885MAPT 1488/4885HPGD 1288/4885 |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | ALDH1A1 517/4885MAPT 653/4885HPGD 524/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | ALDH1A1 517/4885MAPT 653/4885HPGD 524/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | ALDH1A1 399/4885MAPT 661/4885HPGD 544/4885 |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | ALDH1A1 449/4885MAPT 637/4885HPGD 429/4885 |
| US-20060019947-A1 | Therapeutic chromone compounds | HTR1B, HTR3B, HTR1A | ALDH1A1 1200/4885MAPT 1104/4885HPGD 1190/4885 |
| US-20050096312-A1 | Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders | HTR1D, HTR1B, HTR1A | ALDH1A1 2026/4885MAPT 2231/4885HPGD 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.